Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as w...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis-Ajami, Mary Lynn, Wu, Jun, Downton, Katherine, Ludeman, Emilie, Noxon, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999275/
https://www.ncbi.nlm.nih.gov/pubmed/24790409
http://dx.doi.org/10.2147/BTT.S27578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999275/
https://www.ncbi.nlm.nih.gov/pubmed/24790409
http://dx.doi.org/10.2147/BTT.S27578

Ejemplares similares